Dear Editor, I read with interest the original research article describing the use of levosimendan in a rat model of severe verapamil poisoning in the March 2009 issue of the Journal of Medical Toxicology [1] . A number of issues are apparent with this study. First, the authors state: "Although there are no formal studies on the subject, the advent of a class of Ca 2+ sensitizers was thought to afford a novel approach to CCB poisoning." The statement regarding the absence of formal studies with levosimendan in verapamil poisoning is incorrect. We have reported 3 separate animal studies to date investigating the effects of levosimendan in severe verapamil poisoning [2] [3] [4] . The hemodynamic effects of levosimendan have been compared with calcium chloride, norepinephrine, and 4-aminopyridine in severe verapamil poisoning. In all 3 studies heart rate, continuous arterial BP, and cardiac output were monitored. Levosimendan alone produces moderate improvements in cardiac output but not arterial BP compared with the other treatments. When levosimendan is coadministered with each of the other treatments, there is only minimal improvement in BP from that seen at peak verapamil toxicity. Second, Abraham et al note that levosimendan is not only a myocardial calcium sensitizer but also a mild phosphodiesterase inhibitor. They fail to mention that it is also a peripheral vascular potassium channel agonist, producing vasodilatation and reduced afterload, an effect that may be beneficial in some forms of heart failure [5] . We theorize that the K + -channel agonist properties of this agent augment the vasodilatory properties of verapamil and may not be reversible with the addition of other vasoconstrictors. Third, the authors administered levosimendan as 2 relatively large loading doses but also state they cannot guarantee the concentration of the drug used due to difficulty in dissolution of the powdered compound. Levosimendan is commonly administered as a loading dose and lower-dose infusion [6] . The use of 2 bolus doses does not parallel clinical practice with this agent. The second, larger bolus dose may have accelerated the demise of the animals because of significant vasodilation resulting from suddenly increasing levosimendan concentrations. Finally, using death as the major outcome is a very crude measure of drug effect. The authors should have considered recording either invasive arterial blood pressure or at least noninvasive tail cuff blood pressure to better define the effects of levosimendan in verapamil poisoning.
